Rifaximin as a Modulator of Microbial Translocation and Immune Activation
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study is being done to see whether rifaximin, an antibiotic that works in the
intestines, can lower the amount of germs in the intestines of HIV infected persons. It is
possible that when the amount of these germs is lowered, an HIV-infected person's immune
system will become less active and will have a better chance of recovering. Also, the study
will evaluate the safety of using rifaximin in HIV-infected subjects.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)